J. Ryan Watts's most recent trade in Denali Therapeutics Inc was a trade of 50,000 Common Stock done . Disclosure was reported to the exchange on Sept. 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Sep 2025 | 50,000 | 2,152,604 (2%) | 0% | 0 | Common Stock | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 09 Jul 2025 | 495,282 | 253,071 (0%) | 0% | 15 | 7,429,230 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.68 per share. | 09 Jul 2025 | 455,282 | 708,353 (0%) | 0% | 0.7 | 309,592 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jul 2025 | 455,282 | 622,809 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jul 2025 | 40,000 | 20,369 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.28 per share. | 09 Jul 2025 | 40,000 | 748,353 (0%) | 0% | 5.3 | 211,200 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 20.22 per share. | 06 Jan 2025 | 29,266 | 260,721 (0%) | 0% | 20.2 | 591,759 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 20.81 per share. | 06 Jan 2025 | 7,650 | 253,071 (0%) | 0% | 20.8 | 159,197 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 162,540 | 162,540 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 54,180 | 289,987 (0%) | 0% | 0 | Common Stock | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 27.69 per share. | 18 Oct 2024 | 40,000 | 235,807 (0%) | 0% | 27.7 | 1,107,600 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2024 | 40,000 | 1,078,091 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.68 per share. | 18 Oct 2024 | 40,000 | 275,807 (0%) | 0% | 0.7 | 27,200 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 23.79 per share. | 20 Aug 2024 | 2,260 | 235,807 (0%) | 0% | 23.8 | 53,765 | Common Stock |
| Denali Therapeutics Inc | J. Watts Ryan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 17.29 per share. | 13 Feb 2024 | 9,589 | 238,067 (0%) | 0% | 17.3 | 165,794 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 19.78 per share. | 09 Jan 2024 | 7,818 | 2,268,363 (2%) | 0% | 19.8 | 154,640 | Common Stock |
| Denali Therapeutics Inc | J. Watts Ryan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 19.43 per share. | 05 Jan 2024 | 17,483 | 2,276,181 (2%) | 0% | 19.4 | 339,695 | Common Stock |
| Denali Therapeutics Inc | Watts J. Ryan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 268,560 | 268,560 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | J. Ryan Watts | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 89,520 | 272,957 (0%) | 0% | 0 | Common Stock | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 22.59 per share. | 21 Aug 2023 | 2,309 | 2,242,604 (2%) | 0% | 22.6 | 52,160 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 25.03 per share. | 10 Aug 2023 | 2,526 | 2,239,913 (2%) | 0% | 25.0 | 63,226 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2023 | 2,526 | 1,118,091 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.68 per share. | 10 Aug 2023 | 2,526 | 2,242,439 (2%) | 0% | 0.7 | 1,718 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.68 per share. | 16 Jun 2023 | 50,000 | 2,289,913 (2%) | 0% | 0.7 | 34,000 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 50,000 | 1,120,617 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 31.40 per share. | 16 Jun 2023 | 50,000 | 2,239,913 (2%) | 0% | 31.4 | 1,570,000 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Apr 2023 | 24,800 | 1,170,617 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 25.15 per share. | 20 Apr 2023 | 24,800 | 2,239,913 (2%) | 0% | 25.2 | 623,720 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.68 per share. | 20 Apr 2023 | 24,800 | 2,264,713 (2%) | 0% | 0.7 | 16,864 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.68 per share. | 20 Apr 2023 | 200 | 2,240,113 (2%) | 0% | 0.7 | 136 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Apr 2023 | 200 | 1,195,417 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 20 Apr 2023 | 200 | 2,239,913 (2%) | 0% | 25 | 5,000 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.68 per share. | 13 Feb 2023 | 25,000 | 2,264,913 (2%) | 0% | 0.7 | 17,000 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2023 | 25,000 | 1,195,617 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 30.08 per share. | 13 Feb 2023 | 25,000 | 2,239,913 (2%) | 0% | 30.1 | 752,000 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 30.09 per share. | 13 Feb 2023 | 8,815 | 2,239,913 (2%) | 0% | 30.1 | 265,243 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 29.10 per share. | 09 Feb 2023 | 25,000 | 2,229,031 (2%) | 0% | 29.1 | 727,500 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 25,000 | 1,220,617 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.68 per share. | 09 Feb 2023 | 25,000 | 2,254,031 (2%) | 0% | 0.7 | 17,000 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 30.59 per share. | 09 Feb 2023 | 3,433 | 2,229,031 (2%) | 0% | 30.6 | 105,015 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 28.44 per share. | 05 Jan 2023 | 4,800 | 2,223,664 (2%) | 0% | 28.4 | 136,512 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 246,720 | 246,720 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 82,240 | 231,934 (0%) | 0% | 0 | Common Stock | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 28.73 per share. | 03 Jan 2023 | 5,029 | 2,213,464 (2%) | 0% | 28.7 | 144,483 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 33.22 per share. | 19 Aug 2022 | 2,404 | 2,202,993 (2%) | 0% | 33.2 | 79,861 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 34.72 per share. | 11 Feb 2022 | 9,491 | 2,129,648 (2%) | 0% | 34.7 | 329,528 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 64,631 | 0 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.28 per share. | 09 Feb 2022 | 64,631 | 254,522 (0%) | 0% | 5.3 | 341,252 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.60 per share. | 09 Feb 2022 | 6,118 | 260,640 (0%) | 0% | 9.6 | 58,733 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 6,118 | 0 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 37.55 per share. | 09 Feb 2022 | 2,719 | 2,119,442 (2%) | 0% | 37.6 | 102,104 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 44.78 per share. | 05 Jan 2022 | 5,007 | 2,113,361 (2%) | 0% | 44.8 | 224,213 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 186,500 | 186,500 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 62,000 | 213,691 (0%) | 0% | 0 | Common Stock | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 45.30 per share. | 01 Dec 2021 | 9,012 | 2,104,173 (1%) | 0% | 45.3 | 408,244 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 44.39 per share. | 01 Dec 2021 | 8,516 | 2,113,185 (2%) | 0% | 44.4 | 378,025 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 46.35 per share. | 01 Dec 2021 | 805 | 2,103,368 (1%) | 0% | 46.4 | 37,312 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 49.87 per share. | 01 Nov 2021 | 16,674 | 2,121,701 (2%) | 0% | 49.9 | 831,532 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 48.61 per share. | 01 Nov 2021 | 1,659 | 2,138,375 (2%) | 0% | 48.6 | 80,644 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 50.44 per share. | 01 Oct 2021 | 10,782 | 2,144,281 (2%) | 0% | 50.4 | 543,844 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 50.99 per share. | 01 Oct 2021 | 4,247 | 2,140,034 (2%) | 0% | 51.0 | 216,555 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 49.38 per share. | 01 Oct 2021 | 3,304 | 2,155,063 (2%) | 0% | 49.4 | 163,152 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 54.92 per share. | 01 Sep 2021 | 10,892 | 2,158,367 (2%) | 0% | 54.9 | 598,189 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 54.27 per share. | 01 Sep 2021 | 7,441 | 2,169,259 (2%) | 0% | 54.3 | 403,823 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 49.38 per share. | 19 Aug 2021 | 1,626 | 2,177,450 (2%) | 0% | 49.4 | 80,292 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 49.97 per share. | 19 Aug 2021 | 750 | 2,176,700 (2%) | 0% | 50.0 | 37,478 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 51.94 per share. | 02 Aug 2021 | 9,790 | 2,174,076 (2%) | 0% | 51.9 | 508,493 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 50.80 per share. | 02 Aug 2021 | 8,543 | 2,183,866 (2%) | 0% | 50.8 | 433,984 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 77.35 per share. | 01 Jul 2021 | 12,844 | 2,194,868 (2%) | 0% | 77.3 | 993,471 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 76.38 per share. | 01 Jul 2021 | 3,030 | 2,207,712 (2%) | 0% | 76.4 | 231,428 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 77.84 per share. | 01 Jul 2021 | 2,459 | 2,192,409 (2%) | 0% | 77.8 | 191,401 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 60.98 per share. | 01 Jun 2021 | 13,127 | 2,215,948 (2%) | 0% | 61.0 | 800,511 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 62.09 per share. | 01 Jun 2021 | 2,750 | 2,213,198 (2%) | 0% | 62.1 | 170,748 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 62.75 per share. | 01 Jun 2021 | 2,102 | 2,211,096 (2%) | 0% | 62.8 | 131,911 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 63.50 per share. | 01 Jun 2021 | 354 | 2,210,742 (2%) | 0% | 63.5 | 22,479 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 58.45 per share. | 03 May 2021 | 13,997 | 2,233,411 (2%) | 0% | 58.4 | 818,083 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 59.12 per share. | 03 May 2021 | 3,485 | 2,229,926 (2%) | 0% | 59.1 | 206,030 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 59.92 per share. | 03 May 2021 | 851 | 2,229,075 (2%) | 0% | 59.9 | 50,989 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Apr 2021 | 40,000 | 2,265,742 (2%) | 0% | 0 | Common Stock | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 56.88 per share. | 01 Apr 2021 | 8,516 | 2,251,994 (2%) | 0% | 56.9 | 484,356 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 55.52 per share. | 01 Apr 2021 | 5,232 | 2,260,510 (2%) | 0% | 55.5 | 290,486 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 57.31 per share. | 01 Apr 2021 | 4,586 | 2,247,408 (2%) | 0% | 57.3 | 262,842 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 65.63 per share. | 01 Mar 2021 | 5,885 | 2,314,821 (2%) | 0% | 65.6 | 386,209 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 66.55 per share. | 01 Mar 2021 | 3,453 | 2,311,368 (2%) | 0% | 66.5 | 229,780 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 64.42 per share. | 01 Mar 2021 | 3,370 | 2,320,706 (2%) | 0% | 64.4 | 217,106 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 67.69 per share. | 01 Mar 2021 | 3,339 | 2,308,029 (2%) | 0% | 67.7 | 226,017 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 68.46 per share. | 01 Mar 2021 | 1,625 | 2,306,404 (2%) | 0% | 68.5 | 111,246 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 69.65 per share. | 01 Mar 2021 | 594 | 2,305,810 (2%) | 0% | 69.6 | 41,371 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 70.93 per share. | 01 Mar 2021 | 68 | 2,305,742 (2%) | 0% | 70.9 | 4,823 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 70.17 per share. | 11 Feb 2021 | 8,513 | 2,325,036 (2%) | 0% | 70.2 | 597,374 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 71.47 per share. | 11 Feb 2021 | 960 | 2,324,076 (2%) | 0% | 71.5 | 68,610 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2021 | 8,800 | 17,600 | - | - | Restricted Stock Units | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2021 | 8,800 | 2,318,965 (2%) | 0% | 0 | Common Stock | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2021 | 5,516 | 0 | - | - | Restricted Stock Units | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2021 | 5,516 | 2,310,165 (2%) | 0% | 0 | Common Stock | |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 73.24 per share. | 08 Feb 2021 | 2,667 | 2,316,298 (2%) | 0% | 73.2 | 195,328 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 74.05 per share. | 08 Feb 2021 | 1,634 | 2,314,664 (2%) | 0% | 74.1 | 120,999 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 75.07 per share. | 08 Feb 2021 | 811 | 2,313,853 (2%) | 0% | 75.1 | 60,883 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 68.21 per share. | 01 Feb 2021 | 14,222 | 2,308,761 (2%) | 0% | 68.2 | 970,111 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 69.17 per share. | 01 Feb 2021 | 3,552 | 2,305,209 (2%) | 0% | 69.2 | 245,681 | Common Stock |
| Denali Therapeutics Inc | Ryan J. Watts | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 69.69 per share. | 01 Feb 2021 | 560 | 2,304,649 (2%) | 0% | 69.7 | 39,026 | Common Stock |